I know I am beating a dead horse to death on this,

I know I am beating a dead horse to death on this, but I have to ask this in a different way I guess.

Is there anything actually stopping Generex / NGIO from putting out anything concerning if they are proceeding right now with testing, trials in China with the results from the successful testing that they just did? We know in the US, they can't do phase 1 / 2 until they get the IND into the FDA, but again, is China dependent on that or not?

China has their own FDA, so how does the successful testing impact these deals over there and what is Generex / NGIO and their entity over there doing with the successful results concerning the Chinese FDA and moving forward?

Is there anything stopping Generex / NGIO RIGHT NOW from telling their shareholders / future investors this information while they are working on the IND for the FDA here in the United States and also is there anything stopping them from working in China while putting in the IND and waiting on the FDA?

This should be fairly simple for Generex / NGIO to answer or should have answered. The problem is we couldn't ask this type of a question on their CC because the CC call in was broken. This is why a PR or another CC is needed outlining what is currently going on.